AbbVie Inc.
NYSE:ABBVDrug Manufacturers - General
-$4.65 today
- Market cap
- $505.47B
- Beta
- 0.31
- P/E (TTM)
- 105.6
- EPS (TTM)
- $2.05
- Dividend yield
- 3.11%
Volume 4.73M
Average 6.47M
ABBV Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
AbbVie Inc.NYSE: ABBV
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $1.88B fell 8.1% year over year, behind the -4.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 2.7% from the prior quarter. Over 3 fiscal years it compounded at -1.3% a year.
Context
- Depreciation & amortization amounted to 13.3% of revenue in FY2025, down 1.6 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -8.1% toward the trailing-twelve-month pace of -4.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 8.14B USD
- Year-over-year change
- -2.9%
- 4-year CAGR
- -1.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.14B | -2.9% |
| FY2024 | 2024-12-31 | 8.39B | -3.6% |
| FY2023 | 2023-12-31 | 8.7B | +2.7% |
| FY2022 | 2022-12-31 | 8.47B | -0.6% |
| FY2021 | 2021-12-31 | 8.52B | — |
Depreciation & Amortization vs competitors
How ABBV compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -4.8% is the 6th highest of 10, against a peer median of -3.0%.
- Depreciation & amortization amounts to 12.2% of revenue for ABBV, versus a peer median of 9.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $8.09B USD | +9.5% | +2.5% | 8.1% | |
| LTM Jun 2026 | $7.87B USD | -4.8% | -1.3% | 12.2% | |
| LTM Jun 2026 | $6.72B USD | +45.9% | +14.3% | 10.1% | |
| LTM Jun 2026 | $6.58B USD | -3.0% | +9.2% | 10.3% | |
| LTM Sep 2026 | $6.41B USD | +29.8% | +3.0% | 10.3% | |
| LTM Jun 2026 | $5.34B USD | -11.0% | -7.2% | 9.6% | |
| LTM Jun 2026 | $4.67B USD | -15.5% | +14.8% | 12.2% | |
| LTM Jun 2026 | $3.18B USD | -51.1% | -26.9% | 6.5% | |
| LTM Jun 2026 | £2.21B GBP | -34.0% | +2.5% | 6.7% | |
| LTM Jun 2026 | $2.1B USD | +10.9% | +9.5% | 2.6% | |
| Peer median (excluding ABBV) | — | -3.0% | +3.0% | 9.6% | |
Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 11.55B | 11.85B | 4.82B | 4.29B | 4.23B |
| Depreciation & Amortization | 8.52B | 8.47B | 8.7B | 8.39B | 8.14B |
| Deferred Income Tax | (898M) | (1.93B) | (2.89B) | (1.45B) | (492M) |
| Stock-Based Compensation | 692M | 671M | 747M | 911M | 955M |
| Change in Working Capital | (1.32B) | (258M) | 2.81B | (2.78B) | (2.36B) |
| Accounts Receivables | (1.32B) | (1.46B) | 66M | 207M | (1.49B) |
| Inventory | (142M) | (686M) | (417M) | (319M) | (234M) |
| Accounts Payables | 1.63B | 1.61B | 3.84B | 177M | 951M |
| Other Working Capital | (1.49B) | 278M | (676M) | (2.85B) | (1.59B) |
| Other Non-Cash Items | 4.24B | 6.15B | 8.65B | 9.45B | 8.6B |
| Operating Cash Flow | 22.78B | 24.94B | 22.84B | 18.81B | 19.03B |
| Capital Expenditures | (787M) | (695M) | (777M) | (974M) | (1.21B) |
| Acquisitions (Net) | (1.9B) | (794M) | (1.22B) | (17.49B) | (204M) |
| Purchases of Investments | (119M) | (1.44B) | (77M) | (73M) | (35M) |
| Sales of Investments | 98M | 1.53B | 55M | 555M | 76M |
| Other Investing Activities | 366M | 774M | 13M | (2.84B) | (5.27B) |
| Investing Cash Flow | (2.34B) | (623M) | (2.01B) | (20.82B) | (6.64B) |
| Debt Repayment | (8.41B) | (12.43B) | (4.15B) | 7.35B | (327M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 172M |
| Common Stock Repurchased | (934M) | (1.49B) | (1.97B) | (1.71B) | (980M) |
| Dividends Paid | (9.26B) | (10.04B) | (10.54B) | (11.03B) | (11.66B) |
| Other Financing Activities | (430M) | (840M) | (562M) | 172M | 68M |
| Financing Cash Flow | (19.04B) | (24.8B) | (17.22B) | (5.21B) | (12.72B) |
| Effect of Forex Changes | (97M) | (62M) | 5M | (65M) | 42M |
| Net Change in Cash | 1.3B | (545M) | 3.61B | (7.29B) | (295M) |
| Free Cash Flow | 21.99B | 24.25B | 22.06B | 17.83B | 17.82B |
AbbVie Inc.
NYSE:ABBV
Intrinsic Alpha fair value
Locked
Current Price
$285.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.